Leveraging its experience and commercial success, BioTheryX aims to deliver effective therapies to patients with unmet medical needs faster and at a lower cost than traditional biomedical industry practices. They utilize enhanced biology-driven models and prioritized chemistry approaches to identify core molecules for rapid exploitation. By targeting cancer and immune dysfunction, they employ clinically proven translational approaches. Founded in 2007 and headquartered in Chappaqua, New York, BioTheryX is dedicated to improving the quality of life for patients with life-threatening diseases through its innovative small molecule targeted protein degraders. Their pipeline includes a lead product candidate, BTX-1188, currently in a Phase 1/2 clinical trial for acute myeloid leukemia (AML) and solid tumors, with plans to advance three new programs into clinical development within the next three years. For more information, visit www.biotheryx.com.